The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Long‐term evolution of multiple sclerosis disability in the treatment era
Open accessAbstract
Objective: To characterize the accrual of long‐term disability in a cohort of actively treated multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance imaging (MRI) data used in clinical trials have long‐term prognostic value. Methods: This is a prospective study of 517 actively managed MS patients enrolled at a single center. Results: More than 91% of patients were retained, with data ascertained up to 10 years after the baseline visit. At this last assessment, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41% of patients. Subjects with no evidence of disease activity (NEDA) by clinical and MRI criteria during the first 2 years had long‐term outcomes that were no different from those of the cohort as a whole. 25‐OH vitamin D serum levels were inversely associated with short‐term MS disease activity; however, these levels had no association with long‐term disability. At a median time of 16.8 years after disease onset, 10.7% (95% confidence interval [CI] = 7.2–14%) of patients reached an EDSS ≥ 6, and 18.1% (95% CI = 13.5–22.5%) evolved from relapsing MS to secondary progressive MS (SPMS). Interpretation: Rates of worsening and evolution to SPMS were substantially lower when compared to earlier natural history studies. Notably, the NEDA 2‐year endpoint was not a predictor of long‐term stability. Finally, the data call into question the utility of annual MRI assessments as a treat‐to‐target approach for MS care. Ann Neurol 2016;80:499–510
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Self-citationKappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationVitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O'Riordan, J. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 484
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Self-citationEvaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Zivadinov, R., Rudick, R. A., De Masi, R., Nasuelli, D., Ukmar, M., Pozzi–Mucelli, R. S., Grop, A., Cazzato, G., & Zorzon, M. (2001) · Neurology · doi:10.1212/wnl.57.7.1239 · Cited by 346
Disability progression in multiple sclerosis is slower than previously reported
Tremlett, H., Paty, D., & Devonshire, V. (2006) · Neurology · doi:10.1212/01.wnl.0000194259.90286.fe · Cited by 343
Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515616701 · Cited by 289
Self-citationNew natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
Mowry, E. M., Waubant, E., McCulloch, C. E., Okuda, D. T., Evangelista, A. A., Lincoln, R. R., Gourraud, P., Brenneman, D., Owen, M. C., Qualley, P., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23591 · Cited by 270
Self-citationRudick, R. A., Cutter, G., & Reingold, S. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms845oa · Cited by 235
Self-citationNatural history of secondary-progressive multiple sclerosis
Tremlett, H., Zhao, Y., & Devonshire, V. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084264 · Cited by 217
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators (2013) · Annals of Neurology · doi:10.1002/ana.23863 · Cited by 203
Self-citationSpinal cord gray matter atrophy correlates with multiple sclerosis disability
Schlaeger, R., Papinutto, N., Panara, V., Bevan, C., Lobach, I. V., Bucci, M., Caverzasi, E., Gelfand, J. M., Green, A. J., Jordan, K. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24241 · Cited by 196
Self-citationPredictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23758 · Cited by 180
Disability as an outcome in MS clinical trials
Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C., & Noseworthy, J. H. (2008) · Neurology · doi:10.1212/01.wnl.0000313034.46883.16 · Cited by 180
Natural history of multiple sclerosis in a population‐based cohort
Debouverie, M., Pittion‐Vouyovitch, S., Louis, S., Guillemin, F., & for the LORSEP Group (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02241.x · Cited by 163
Bevan, C. J., & Cree, B. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5486 · Cited by 144
Self-citationGray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS
Rudick, R. A., Lee, J. C., Nakamura, K., & Fisher, E. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.11.018 · Cited by 133
One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis
Prosperini, L., Gallo, V., Petsas, N., Borriello, G., & Pozzilli, C. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02708.x · Cited by 128
MRI as an outcome in multiple sclerosis clinical trials
Däumer, M., Neuhaus, A. A., Morrissey, S., Hintzen, R. Q., & Ebers, G. C. (2008) · Neurology · doi:10.1212/01.wnl.0000336916.38629.43 · Cited by 114
Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls
Nickles, D., Chen, H. P., Li, M. M., Khankhanian, P., Madireddy, L., Caillier, S. J., Santaniello, A., Cree, B., Pelletier, D., Hauser, S. L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt267 · Cited by 110
Self-citationAggregation of multiple sclerosis genetic risk variants in multiple and single case families
Gourraud, P., McElroy, J. P., Caillier, S. J., Johnson, B. A., Santaniello, A., Hauser, S. L., & Oksenberg, J. R. (2010) · Annals of Neurology · doi:10.1002/ana.22323 · Cited by 108
Self-citationThe natural history of primary progressive MS in British Columbia, Canada
Tremlett, H. L., Paty, D. W., & Devonshire, V. A. (2005) · Neurology · doi:10.1212/01.wnl.0000188880.17038.1d · Cited by 102
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis
Schlaeger, R., Papinutto, N., Zhu, A. H., Lobach, I. V., Bevan, C. J., Bucci, M., Castellano, A., Gelfand, J. M., Graves, J., Green, A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0993 · Cited by 100
Self-citationGoodin, D. S., Traboulsee, A. L., Knappertz, V. A., Reder, A. T., Li, D., Langdon, D. W., Wolf, C., Beckmann, K., Konieczny, A., Ebers, G. C., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301178 · Cited by 94
Self-citationMRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS
Sormani, M. P., Filippi, M., Stefano, N. D., Ebers, G., & Daumer, M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6b8f · Cited by 91
Vitamin D in African Americans with multiple sclerosis
Gelfand, J., Cree, B., McElroy, J., Oksenberg, J. R., Green, R., Mowry, E. M., Miller, J. W., Hauser, S. L., & Green, A. J. (2011) · Neurology · doi:10.1212/wnl.0b013e31821cccf5 · Cited by 73
Self-citationMassacesi, L., Tramacere, I., Amoroso, S., Battaglia, M. A., Benedetti, M. D., Filippini, G., Mantia, L. L., Repice, A. M., Solari, A., Tedeschi, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113371 · Cited by 61
Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
Castillo‐Triviño, T., Mowry, E. M., Gajofatto, A., Chabas, D., Crabtree‐Hartman, E., Cree, B., Goodin, D. S., Green, A., Okuda, D. T., Pelletier, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016664 · Cited by 58
Self-citationVariations in functioning and disability in multiple sclerosis
Ytterberg, C., Johansson, S., Andersson, M., Holmqvist, L. W., & von Koch, L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0767-0 · Cited by 54
Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
Oh, J., & O'Connor, P. W. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614546855 · Cited by 52
Tedeholm, H., Skoog, B., Lisovskaja, V., Runmarker, B., Nerman, O., & Andersen, O. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7674-y · Cited by 47
Cook, S. D., Dhib-Jalbut, S. S., Dowling, P. C., Durelli, L., Ford, C. C., Giovannoni, G., Halper, J., Harris, C. J., Herbert, J., Li, D., et al. (2012) · International Journal of MS Care · doi:10.7224/1537-2073-14.3.105 · Cited by 44
Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients
Debouverie, M., Laforest, L., Ganse, E. H. V., Guillemin, F., & for the LORSEP Group (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508097919 · Cited by 42
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
Michel, L., Vukusic, S., Seze, J. D., Ducray, F., Ongagna, J. C., Lefrere, F., Jacq-Foucher, M., Confavreux, C., Wiertlewski, S., & Laplaud, D. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305298 · Cited by 39
Romeo, M. A. L., Boneschi, F. M., Rodegher, M., Esposito, F., Martinelli, V., & Comı, G. (2013) · European Journal of Neurology · doi:10.1111/ene.12119 · Cited by 32
Determining the Presence of Reliable Change over Time in Multiple Sclerosis
Barker-Collo, S. L., & Purdy, S. C. (2013) · International Journal of MS Care · doi:10.7224/1537-2073.2013-007 · Cited by 17
Estimating Typical Multiple Sclerosis Disability Progression Speed from Clinical Observations
Brown, M. G., Asbridge, M., Hicks, V., Kirby, S., Murray, T. J., Andreou, P., & Lin, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105123 · Cited by 9
Cited by
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationThompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Self-citationDiagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Self-citation
Metadata
- Authors
- University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., Mowry, E., Okuda, D. T., Pelletier, D., von Büdingen, H. ‐., Zamvil, S. S., Agrawal, A., Caillier, S., Ciocca, C., Gomez, R., Kanner, R., Lincoln, R., Lizee, A., Qualley, P., Santaniello, A., Suleiman, L., Bucci, M., Panara, V., Papinutto, N., Stern, W. A., Zhu, A. H., Cutter, G. R., Baranzini, S., Henry, R. G., & Hauser, S. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2016-08-13
- Volume
- 80
- Issue
- 4
- Pages
- 499-510
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2489432788
- Cited by
- 440
- References
- 54
- FWCI
- 35.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.